Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.44 |
| ▸ | PARP1 | P09874 | 7/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.39 |
| ▸ | UBE2N | P61088 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | KDM4B | O94953 | 1/20 | 0.36 |
| ▸ | KDM5C | P41229 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL325052 | 0.86 | PARP1 (0.55) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL29858985 | 0.80 | L3MBTL1 (0.40) | L3MBTL1PARP1PDPK1CA12ALOX15 | |
| Quinazolinone SCHEMBL31483770 | 0.79 | PARP1 (0.72) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| Quinazolinone SCHEMBL28036592 | 0.79 | PARP1 (0.72) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL22397327 | 0.75 | L3MBTL1 (0.45) | L3MBTL1ALOX15SMN1; SMN2UBE2NKDM4E | |
| Benzimidazole SCHEMBL2073386 | 0.73 | RAB9A (0.50) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| Benzimidazole SCHEMBL2020186 | 0.73 | RAB9A (0.50) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| Benzimidazole SCHEMBL29397040 | 0.73 | RAB9A (0.50) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| Benzimidazole SCHEMBL2075174 | 0.73 | RAB9A (0.50) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL29424148 | 0.71 | L3MBTL1 (0.38) | L3MBTL1PARP1ALOX15SMN1; SMN2UBE2N |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391671-B2 | Allosteric EGFR inhibitors and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20220411404-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391671-B2 | Allosteric EGFR inhibitors and methods of use thereof | EGFR, ERBB2, ERBB3 | L3MBTL1 3418/4885PARP1 3221/4885PDPK1 358/4885 |
| US-20220411404-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | L3MBTL1 3418/4885PARP1 3221/4885PDPK1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.